MiR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1

Oncogene

Volumn 33, Issue 25, 2014, Pages 3267-3276

  Shang, Y ^a   Zhang, Z ^a   Liu, Z ^a   Feng, B ^a   Ren, G ^a   Li, K ^a   Zhou, L ^a   Sun, Y ^a   Li, M ^a   Zhou, J ^a   An, Y ^b   Wu, K ^a   Nie, Y ^a   Fan, D ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

ABCB1; drug resistance; gastric cancer; miR 508 5p; ZNRD1

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 508 5P; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN ZNRD1; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; GENE OVEREXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; STOMACH CANCER;

3' UNTRANSLATED REGIONS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; MICRORNAS; P-GLYCOPROTEIN; RNA, MESSENGER; STOMACH NEOPLASMS; TRANSFECTION; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908022850     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.297     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Fodale V, Pierobon M, Liotta L, Petricoin E. Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Cancer J 2011; 17: 89-95.
3. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31: 1869-1883.
4. Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel AH. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. Int J Cancer 2012; 132: 2439-2447.
5. Zhu H, Liu Z, Tang L, Liu J, Zhou M, Xie F et al. Reversal of P-gp and MRP1-mediated multidrug resistance by H6, a gypenoside aglycon from Gynostemma pentaphyllum, in vincristine-resistant human oral cancer (KB/VCR) cells. Eur J Pharmacol 2012; 696: 43-53.
6. Tsuji K, Wang YH, Takanashi M, Odajima T, Lee GA, Sugimori H et al. Overexpression of lung resistance-related protein and P-glycoprotein and response to induction chemotherapy in acute myelogenous leukemia. Hematol Rep 2012; 4: e18.
7. Han JY, Hong EK, Choi BG, Park JN, Kim KW, Kang JH et al. Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer. Med Oncol 2003; 20: 355-362.
8. Michaud WA, Nichols AC, Mroz EA, Faquin WC, Clark JR, Begum S et al. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res 2009; 15: 1645-1654.
9. Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, Hu YY et al. Expression of BclxL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 2005; 96: 287-295.
10. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275-283.
11. Plenchette S, Cheung HH, Fong WG, LaCasse EC, Korneluk RG. The role of XAF1 in cancer. Curr Opin Investig Drugs 2007; 8: 469-476.
12. Guo W, Zhao YP, Jiang YG, Wang RW, Hong L, Fan DM. Upregulation of ZNRD1 enhances cisplatin resistance in human esophageal cancer cells by regulation of ERCC1 and Bcl-2. Tumour Biol 2008; 29: 188-194.
13. Hong L, Qiao T, Han Y, Han S, Zhang X, Lin T et al. ZNRD1 mediates resistance of gastric cancer cells to methotrexate by regulation of IMPDH2 and Bcl-2. Biochem Cell Biol 2006; 84: 199-206.
14. Zhao L, Pan Y, Gang Y, Wang H, Jin H, Tie J et al. Identification of GAS1 as an epirubicin resistance-related gene in human gastric cancer cells with a partially randomized small interfering RNA library. J Biol Chem 2009; 284: 26273-26285.
15. Shi Y, Zhai H, Wang X, Han Z, Liu C, Lan M et al. Ribosomal proteins S13 and L23 promote multidrug resistance in gastric cancer cells by suppressing drug-induced apoptosis. Exp Cell Res 2004; 296: 337-346.
16. Chen C.Z. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 2005; 353: 1768-1771.
17. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
18. Catuogno S, Cerchia L, Romano G, Pognonec P, Condorelli G, de Franciscis V. miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene 2012; 27: 1-11.
19. Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao H et al. Reduced miR-128 in breast tumorinitiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res 2011; 17: 7105-7115.
20. Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M et al. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 2012; 31: 432-445.
21. Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C et al. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2011; 30: 1082-1097.
22. Ma K, He Y, Zhang H, Fei Q, Niu D, Wang D et al. DNA methylation- regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Biol Chem 2012; 287: 5639-5649.
23. Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009; 28: 4065-4074.
24. Zhao X, Yang L, Hu J. Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 2011; 30: 55.
25. Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang B et al. miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol 2012; 29: 384-391.
26. Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J et al. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 2012; 69: 723-731.
27. Zhu W, Shan X, Wang T, Shu Y, Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010; 127: 2520-2529.
28. Zhu W, Shan X, Wang T, Shu Y, Liu P. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008; 123: 372-379.
29. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008; 7: 2152-2159.
30. Feng DD, Zhang H, Zhang P, Zheng YS, Zhang XJ, Han BW et al. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med 2011; 15: 2164-2175.
31. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 2008; 76: 582-588.
32. Feng DD, Zhang H, Zhang P, Zheng YS, Zhang XJ, Han BW et al. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukemia. J Cell Mol Med 2011; 15: 2164-2175.
33. Zhang H, Li M, Han Y, Hong L, Gong T, Sun L et al. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 2010; 55: 2545-2551.
34. Seres M, Cholujova D, Bubenckova T, Breier A, Sulova Z. Tunicamycin depresses p-glycoprotein glycosylation without an effect on its membrane localization and drug efflux activity in l1210 cells. Int J Mol Sci 2011; 12: 7772-7784.
35. Gribar JJ, Ramachandra M, Hrycyna CA, Dey S, Ambudkar SV. Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system. J Mem Biol 2000; 173: 203-214.
36. Kramer R, Weber TK, Arceci R, Ramchurren N, Kastrinakis WV, Steele Jr G et al. Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype. Br J Cancer 1995; 71: 670-675.
37. Hong L, Ning X, Shi Y, Shen H, Zhang Y, Lan M et al. Reversal of multidrug resistance of gastric cancer cells by down-regulation of ZNRD1 with ZNRD1 siRNA. Br J Biomed Sci 2004; 61: 206-210.
38. Hong L, Ning X, Shi Y, Shen H, Zhang Y, Lan M et al. Overexpression of ZNRD1 promotes multidrug-resistant phenotype of gastric cancer cells through upregulation of P-glycoprotein. Cancer Biol Ther 2004; 3: 377-381.
39. Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT et al. Identification of microRNA-21as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010; 5: e10630.
40. Nishida N, Yamashita S, Mimori K, Sudo T, Tanaka F, Shibata K et al. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol 2012; 19: 3065-3071.
41. Eitan R, Kushnir M, Lithwick-Yanai G, David MB, Hoshen M, Glezerman M et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol 2009; 114: 253-259.
42. Kim CH, Kim HK, Rettig RL, Kim J, Lee ET, Aprelikova O et al. miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genomics 2011; 4: 79.
43. Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer 2012; 12: 613-626.
44. Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011; 19: 232-243.
45. Wang Y, Baskerville S, Shenoy A, Babiarz JE, Baehner L, Blelloch R. Embryonic stem cell-specific microRNAs regulate the G1-S transition and promote rapid proliferation. Nat Genet 2008; 40: 1478-1483.
46. Huang DY, Mock M, Hagenbuch B, Chan S, Dmitrovic J, Gabos S et al. Dynamic cytotoxic response to microcystins using microelectronic sensor arrays. Environ Sci Technol 2009; 43: 7803-7809.